Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
This publication has been retracted by the Editor due to the identification of falsified figure images and manuscript content that raise concerns regarding the credibility of the study and the manuscr
APA
Song H, Zhang J, et al. (2022). Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.. Medical science monitor : international medical journal of experimental and clinical research, 28, e936571. https://doi.org/10.12659/MSM.936571
MLA
Song H, et al.. "Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.." Medical science monitor : international medical journal of experimental and clinical research, vol. 28, 2022, pp. e936571.
PMID
35250023
Abstract
This publication has been retracted by the Editor due to the identification of falsified figure images and manuscript content that raise concerns regarding the credibility of the study and the manuscript. Reference: Vemurafenib Hao Song, Jinna Zhang, Liang Ning, Honglai Zhang, Dong Chen, Xuelong Jiao, Kejun Zhang. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Med Sci Monit, 2018; 24: 3002-3010. DOI: 10.12659/MSM.910084.
같은 제1저자의 인용 많은 논문 (5)
- Case Report: Ataxia telangiectasia with severe hemorrhagic cystitis.
- Dual-input spatio-temporal transformer model: Predicting the efficacy of NACT in breast cancer based on DCE-MRI images.
- Decoding hepatocellular carcinoma prognosis: a machine learning-derived methylation signature integrating transcriptomic and tumor microenvironment insights.
- Hijacking ERAD for targeted degradation of transmembrane proteins.
- AGTPBP1 promotes breast cancer progression via the EVPL/ERK signaling axis.